China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Google Secures Pentagon AI Deal for Classified Projects 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
IRVINE, Calif., Feb. 17, 2016 -- CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis and postnatal developmental disorders and pre-implantation genetic screening (PGS) services, announces that it has received a letter from the NASDAQ Listing Qualifications Staff notifying the Company that it has regained full compliance with NASDAQ's minimum bid price continued listing requirement.
The letter, received February 16, 2016, noted that the closing bid price of CombiMatrix’s common stock has been at $1.00 per share or higher for the last 10 consecutive business days, from February 1, 2016 to February 12, 2016. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed. There can be no assurance, however, that the Company will be able to maintain compliance with the minimum bid price requirement in the future.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in pre-implantation genetic screening, miscarriage analysis, prenatal and pediatric diagnostics, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray, standardized and customized fluorescence in situ hybridization (FISH) and high-resolution karyotyping. CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making. Additional information about CombiMatrix is available at www.combimatrix.com or by calling (800) 710-0624.
Company Contact: Mark McDonough President & CEO, CombiMatrix Corporation (949) 753-0624 Investor Relations Contact: LHA Jody Cain (310) 691-7100 [email protected]
